A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight \>45 kg (99 lbs). * An informed consent document signed and dated by the subject or a legally acceptable representative. Exclusion Criteria: * A history of drug induced agranulocytosis and history of liver and hematological problems while taking amodiaquine. * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen.